Key facts
- American Gene Technologies’s last known valuation is $265.0M (Feb 2019).
- It has raised $81.3M; the latest was Later Stage VC ($310K) in Dec 2025.
- Notable investors include Alumni Ventures, Gaingels, Ossian Capital, ROC Venture Group, 10X Capital — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for American Gene Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for American Gene Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About American Gene Technologies
Developer of gene and cell therapy designed to cure infectious diseases, cancers, and inherited disorders. The company's therapy has three patents to make the cell product functionally cure HIV individuals, and ten patents for its immuno-oncology approach to stimulate gamma-delta T cells to eliminate a variety of human solid tumors has developed a synthetic gene, enabling physicians to get effective drugs to treat Phenylketonuria (PKU) patients.
- Sector
- Healthcare
- HQ
- Rockville, MD, United States
- Founded
- 2007
- Employees
- 25
- Website
- americangene.com/
- Ownership
- Privately Held (backing)
American Gene Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in American Gene Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on American Gene Technologies in its N-PORT filings yet. We sweep new filings monthly.